SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Electronic Arts, Inc. engages in the development, marketing, publication, and distribution of games, content, and services for game consoles, PCs, mobile phones, and tablets. The company develops and publishes games and services across various genres, such as sports, first-person shooter, action, role-playing, and simulation primarily under the Battlefield, The Sims, Apex Legends, Anthem, Need for Speed, and Plants v. Zombies brands, and license games, including FIFA, Madden NFL, and Star Wars brands. The firm also provides advertising services and licenses its games to third parties to distribute and host its games. It markets and sells its games and services through digital distribution channels, as well as through retail channels, such as mass-market retailers, electronics specialty stores, and game software specialty stores. The company was founded by William M. Hawkins III and William Gordon in 1982 and is headquartered in Redwood City, CA.

Electronic Arts, Inc.

Electronic Arts is trending amid reports of a potential leveraged buyout valued at $50 billion, backed by investors like Silver Lake and Saudi Arabia's Public Investment Fund, leading to a surge in stock price and trading halts. The community is discussing the potential buyout price and impact on other video game stocks, while also reflecting on the company's past performance and future prospects. Some investors express concerns about debt, the quality of games, and the implications for the gaming sector as a whole.

The project is a derivative of Fartcoin. The Fartcoin deployer has deployed this token because the President at Bone Fide Wealth tweeted about "A client just called and asked me if there’s going to be a Fartcoin ETF this year." Since the Elon narrative is has been running this one has come to existence. The token is following different narratives like Fartcoin, SPX500 and other big memes following the Trump narrative.

Elon Trump Fart

ETF500.X is trending as the community rallies behind the self-proclaimed first ETF on Solana, anticipating substantial gains. Discussions center on accumulating the asset, with many highlighting the strong community and the potential for meme season to drive significant growth. Some users are pointing out the presence of known pumpers or scammers.

bioAffinity Technologies, Inc. operates as a development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The firm develops proprietary in-vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells. The company was founded on March 26, 2014 and is headquartered in San Antonio, TX.

BioAffinity Technologies Inc

BioAffinity Technologies ($BIAF) is trending due to positive case studies highlighting the effectiveness of its CyPath Lung test for early lung cancer detection, potentially reducing unnecessary biopsies. The stock's low float and recent reverse split are fueling community discussions about a potential squeeze, with some anticipating a run to higher price levels. Bullish sentiment revolves around the company's cancer detection technology and its potential for a large market opportunity.

Take-Two Interactive Software, Inc. engages in the development, publishing, and marketing of interactive software games. Its products are designed for console systems, handheld gaming systems, and personal computers, including smart phones and tablets, and are delivered through physical retail, digital download, online platforms, and cloud streaming services. The company was founded by Ryan A. Brant in 1993 and is headquartered in New York, NY.

Take-Two Interactive Software, Inc.

Take-Two Interactive is trending due to speculation and community buzz following the release of the second GTA VI trailer, despite the game's release being pushed to May 2026.  Enthusiasm remains high with investors focused on the long-term potential of GTA VI and its impact on the gaming industry, as well as potential revenue from recurring online engagement.

MP Materials Corp. engages in the production and marketing of rare earth specialty materials. It operates through the Materials and Magnetics segments. The Materials segment focuses on the operation of Mountain Pass, which produces refined rare earth oxides and related products, as well as rare earth concentrate products. The Magnetics segment is involved in the operation of Independence Facility, where the company began production of magnetic precursor products. The company was founded by James Henry Litinsky and Michael Rosenthal in 2017 and is headquartered in Las Vegas, NV.

MP Materials Corporation

MP Materials is trending amid discussions about government support and its role in the rare earth supply chain, with some seeing it as a beneficiary of efforts to counter China's dominance in the sector. Community members are weighing the stock's valuation and potential catalysts, including upcoming financial reports and long-term contracts. There's also debate around potential government deals as well as comparing it to other companies in the space.

BTQ Technologies Corp

BTQ is trending as investors discuss the potential impact of a $300 million registration for dilution after its NASDAQ debut, with some expressing disappointment and others viewing it as a long-term buying opportunity. Community members are debating the company's valuation and revenue prospects in the quantum cybersecurity space, while awaiting news about Robinhood availability. Some investors remain bullish, citing a deal with Danal and the potential for BTQ to become a leader in quantum-safe technology.

Aqua Metals, Inc. engages in reinventing metal recycling technologies. Its patented technology, AquaRefining, replaces polluting furnaces and hazardous chemicals with electricity-powered electroplating to recover valuable metals and materials from spent batteries with higher purity, lower emissions, and minimal waste. The company was founded by Stephen R. Clarke, Thomas Murphy, and Selwyn Mould on June 20, 2014 and is headquartered in Reno, NV.

Aqua Metals Inc

AQMS is trending due to recent momentum and speculative interest in low-float stocks, particularly within the lithium sector. The community is actively discussing the stock's potential for a significant breakout and potential short squeeze, drawing comparisons to other high-flying stocks in the sector. Aqua Metals' participation in an upcoming battery show and a focus on critical minerals may be contributing to the heightened interest.

Rezolve AI Plc operates in the mobile commerce industry with its cutting-edge engagement platform powered by artificial intelligence and machine learning. It develops AI-based mobile commerce and engagement solutions, simplifying the purchasing process by providing relevant information and facilitating seamless transactions with a single tap. The company enables retailers, brands, and manufacturers to create dynamic connections with consumers across mobile and desktop devices. Rezolve Ai was founded in 2016 and is headquartered in London, the United Kingdom.

Rezolve AI PLC .

Rezolve AI Limited

Rezolve AI is trending as investors discuss a recently closed, oversubscribed $200 million financing round and its potential impact on the company's growth trajectory ahead of earnings. Community members are weighing the significance of institutional backing against possible dilution, debating whether this move sets the stage for future acquisitions or indicates underlying financial challenges. The involvement of key partners like Microsoft and Google, as well as upcoming earnings on October 1st, are also central to the conversation.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BCRX is trending amidst investor frustration over the stock's underperformance despite positive earnings and revenue growth, with some speculating about a potential buyout or acquisition to unlock shareholder value. The community is actively discussing the reasons behind the stock's stagnant price, including potential market manipulation and the company's future strategy. Discussions include both the potential for a short squeeze, and concerns about future data readouts.

Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. The firm is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.

Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals ($CRNX) is trending as the community discusses its potential, driven by the recent FDA approval of Palsonify for acromegaly. Community members are actively discussing the steady share price post-approval and anticipating a second leg up, with some suggesting the stock could reach triple digits in the coming year. Bullish sentiment is fueled by the drug's clean label, expansion into Europe, and convenience for patients, while others point to high institutional ownership and potential for a short squeeze.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of bioAffinity Technologies (BIAF) soared 79% on Friday after the company released three additional case studies, including one in which the use of its CyPath Lung test led to the detection of lung cancer at an early, possibly curable stage.The company also <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20250926999689/en/bioAffinity-Technologies-Adds-to-Growing-Number-of-Case-Studies-Demonstrating-Clinical-Value-of-CyPath-Lung">stated</a> that two potentially risky invasive procedures were avoided for patients facing difficult healthcare choices by using the test.CyPath Lung is a non-invasive test designed to enhance the early detection of lung cancer in patients at high risk for the disease. It uses advanced flow cytometry and artificial intelligence (AI) to identify cell populations in a patient’s sputum that indicate malignancy. In clinical studies, it was demonstrated that CyPath Lung had a sensitivity of 92%, specificity of 87%, and an accuracy of 88%.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/BIAF">BIAF stock</a> rose from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘extremely high’ levels.BioAffinity stated that the three new cases were provided by a Texas pulmonologist who has been using the test for over a year. While early-stage lung cancer was diagnosed in 68-year-old Samuel with the help of the test, David avoided an unnecessary biopsy after the test came out negative. Lisa, with a previous diagnosis of lung cancer, proceeded with radiation therapy after a positive CyPath Lung result without performing a biopsy, as she might not have been healthy enough for the procedure.“We believe CyPath Lung can be a transformative tool in the lung cancer diagnostic pathway, especially when imaging results are inconclusive. A positive CyPath Lung result can lead to earlier diagnosis and treatment, and a negative result can spare patients from unnecessary invasive procedures,” Chief Medical Officer Gordon Downie said.BIAF stock is down 78% this year and by 90% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/pharmaceutical-tariffs-a-light-at-the-end-of-the-trump-tunnel-for-big-pharma-says-jefferies/chDViCCR3e4">Pharmaceutical Tariffs ‘A Light At The End Of The Trump Tunnel’ For Big Pharma, Says Jefferies</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

bioAffinity Technologies Stock Surged A Whopping 79% Today – Here’s An Important Update

The company reported that the use of its CyPath Lung test enabled the detection of lung cancer at an early stage.

Equity

The company reported that the use of its CyPath Lung test enabled the detection of lung cancer at an early stage.


BIAF Stock Down Following Q2 Earnings Despite CyPath Lung Growth

bioAffinity shifts its focus on CyPath Lung as the second-quarter 2025 loss widens, with rising adoption and new market expansion underway.

The Zacks Analyst Blog Highlights Meta Platforms, ServiceNow, Booking, Vaso and bioAffinity Technologies

META, NOW, and BKNG lead with AI-driven growth and digital transformation tailwinds, while VASO and BIAF offer speculative upside.

Top Research Reports for Meta Platforms, ServiceNow & Booking

META, NOW, and BKNG gain ground as AI, digital transformation, and global travel trends fuel top-line momentum.

BIAF Stock Rises Post Q1 Earnings Despite Revenue Decline

U.S. stock markets spiraled lower last week as President Donald Trump's sweeping reciprocal tariffs rattled global investors.&nbsp;But while tech and industrials bore the brunt of the selloff, healthcare stocks showed surprising resilience — living up to their reputation as a defensive haven during periods of economic uncertainty.Here are three names from the sector that stood out&nbsp;with staggering weekly gains, offering retail traders on Stocktwits a rare dose of optimism in an otherwise chaotic week:iCoreConnect Inc (ICCT) - 1,579% weekly gain&nbsp;Ocoee, Florida-based iCoreConnect offers software-as-a-service for the healthcare market. Last week, there were no major news catalysts for the stock, although it has seen heavy trading volume since the beginning of April.&nbsp;On Stocktwits, sentiment remained 'extremely bullish' last week amid stunning gains, with followers jumping by 69% and message volume exploding by over 40,400%.&nbsp; &nbsp;<figure class="image"><img style="aspect-ratio:1318/316;" src="https://news.stocktwits-cdn.com/ICCT_sentiment_and_message_volume_as_of_April_6_png_16855887e8.webp" alt="ICCT sentiment and message volume as of April 6.png" width="1318" height="316"><figcaption>ICCT sentiment and message volume as of April 6. | source: Stocktwits</figcaption></figure>Recent posts suggest that retail traders anticipate a major development, though many dismissed the possibility of another equity offering —something the company has done multiple times.Last year, the company received the backing of several state dental associations for its cloud solutions and made some strategic acquisitions.BioAffinity Technologies Inc (BIAF) - 163% weekly gain&nbsp;San Antonio, Texas-based BioAffinity is a company focused on making products for the early detection of cancers. Its initial product, CyPath Lung, uses a patient's sputum and proprietary automated flow cytometry data analysis to diagnose early-stage lung cancer accurately.Last week, Maxim — the sole research firm covering the stock — downgraded BioAffinity to 'Hold' from 'Buy' after the company posted annual financial results.BioAffinity's 2024 revenue increased 270% from a year earlier, primarily due to the acquisition of Precision Pathology Laboratory Services (PPLS). However, the company's net loss also increased due to higher operating expenses.In March, BioAffinity said it expects to realize most of its planned $4 million in annual cost savings through workforce and operational cuts at PPLS and improving operational efficiency by cutting supply and service costs.&nbsp;<figure class="image"><img style="aspect-ratio:1318/316;" src="https://news.stocktwits-cdn.com/BIAF_sentiment_and_message_volume_as_of_April_6_png_0a9f433739.webp" alt="BIAF sentiment and message volume as of April 6.png" width="1318" height="316"><figcaption>BIAF sentiment and message volume as of April 6. | source: Stocktwits</figcaption></figure>On Stocktwits, sentiment ended Friday higher in the 'extremely bullish' zone amid a 3,750% spike in weekly message volume.Alaunos Therapeutics Inc (TCRT) - 102% weekly gain&nbsp;Houston, Texas-based Alaunos is a biotech firm that also rocketed last week with virtually no major news catalysts, with Stocktwits sentiment flipping to 'extremely bullish' from 'neutral.'&nbsp;Regulatory filings from April 1 revealed that senior executives, including interim CEO Dale Curtis Hogue, exercised options to buy 7,000 shares at $1.46 apiece.&nbsp;The company's annual 10-K report also showed that Alaunos' 2024 revenue doubled to $10,000, while net loss shrank to $4.6 million from $35.1 million a year earlier.&nbsp;Alaunos significantly cut expenses by winding down clinical programs, such as its costly TCR-T clinical trial, and reducing headcount.&nbsp;The company is exploring strategic options such as mergers, partnerships, or asset sales.&nbsp;<figure class="image"><img style="aspect-ratio:1318/316;" src="https://news.stocktwits-cdn.com/TCRT_sentiment_and_message_volume_as_of_April_6_png_163e68145a.webp" alt="TCRT sentiment and message volume as of April 6.png" width="1318" height="316"><figcaption>TCRT sentiment and message volume as of April 6. | source: Stocktwits</figcaption></figure>Alaunos is now focused on its small molecule oral obesity drug program, which aims to offer a differentiated alternative to injectable GLP-1 therapies by preserving lean muscle mass.&nbsp;Alaunos regained Nasdaq compliance in February and expects its current cash reserves to last into the second quarter.For updates and corrections, email newsroom[at]stocktwits[dot]com.

These 3 Healthcare Stocks Show Serious Muscle Amid Trump Tariff Turmoil: Are Retail Traders Feeling Bullish?

iCoreConnect, BioAffinity and Alaunos Therapeutics posted strong gains last week amid heavy trading volume.

WallachBeth Capital Announces Closing of bioAffinity Technologies Warrant Inducement Transaction for Aggregate Gross Proceeds of $1.4 Million

WallachBeth Capital Announces Closing of bioAffinity Technologies Warrant Inducement Transaction for Aggregate Gross Proceeds of $1.4 Million WallachBeth Capital Announces Closing of bioAffinity...

bioAffinity Technologies Announces Closing of Warrant Inducement Transaction for Aggregate Gross Proceeds of $1.4 Million

bioAffinity Technologies, Inc. (NASDAQ: BIAF and BIAFW) announced today it has closed its previously announced warrant exercise agreements with four existing accredited investors to exercise certain...

WallachBeth Capital Announces bioAffinity Technologies Warrant Inducement for Aggregate Gross Proceeds of $1.4 Million

WallachBeth Capital Announces bioAffinity Technologies Warrant Inducement for Aggregate Gross Proceeds of $1.4 Million WallachBeth Capital Announces bioAffinity Technologies Warrant Inducement for...

bioAffinity Technologies Announces Warrant Inducement for Aggregate Gross Proceeds of $1.4 Million

bioAffinity Technologies, Inc. (NASDAQ: BIAF and BIAFW) announced today it has entered into warrant exercise agreements with three existing accredited investors to exercise certain outstanding...

Will the U.S. government shut down in 2025? 
 
*Powered by Polymarket

BIAF
BioAffinity Technologies Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest BIAF News

BIAF BioAffinity Technologies Inc